Effect of IFN-γ on Innate Immune Cells

• Status: Completed
• Trial end date: 2019-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Interferon-gamma; Interferons

Criteria

Inclusion Criteria:

1. Healthy adults over the age of 18 years up to 60 years.

2. At time of screening subject is well and healthy;

3. Acute infections resolved;

4. Subject off treatment medications;

5. No diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications.

6. Non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator.

Exclusion Criteria:

1. Pregnancy.

2. History of current infection;

3. Two weeks from most recent intercurrent infection;

4. History of recurrent infections or immunodeficiency.